

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Genscript Biotech Corporation

金斯瑞生物科技股份有限公司*

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 1548)

VOLUNTARY ANNOUNCEMENT RESEARCH AND DEVELOPMENT UPDATE

This announcement is made by Genscript Biotech Corporation (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis.

The board (the “**Board**”) of directors (the “**Directors**”) of the Company is pleased to announce that the Group has achieved promising results in the joint research and development effort with various international research and development institutions in the field of synthetic genomics with the aim to newly design and synthesize all 16 *saccharomyces cerevisiae* chromosomes, at the total length of 12 million base pair (the “**Joint Research and Development Project**”).

Under the Joint Research and Development Project, scientists from the Group and various international institutions have completed the design, assembling and synthesis of five chromosomes, of which the Group has been involved in the synthesis of the number six chromosome. The Board is pleased to announce that the Joint Research and Development Project yields promising results, which has been published in *Science*, a leading international science journal, entitled “Synthesis, Debugging, and Effects of Synthetic Chromosome Consolidation: synVI and Beyond”, on March 10, 2017.

The Group believes that the Joint Research and Development Project has significantly widened the application of gene modified yeast, which will facilitate the increase in efficacy and improvement in quality of the industrial production of vaccines, drugs, and specific compounds. The Group further believes that the promising research and development results will boost the Group's plan to capture the growth opportunities in the synthetic biology market in the future.

By order of the Board
Genscript Biotech Corporation
Zhang Fangliang
Chairman and Chief Executive Officer

Hong Kong, 10 March 2017

As at the date of this announcement, the executive Directors are Dr. Zhang Fangliang, Ms. Wang Ye and Mr. Meng Jiange; the non-executive Directors are Dr. Wang Luquan, Mr. Huang Zuie-Chin and Mr. Pan Yuexin; and the independent non-executive Directors are Mr. Guo Hongxin, Mr. Dai Zumian and Ms. Zhang Min.

** For identification purposes only*